Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Indaptus Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 15 | 1 | 17 | +3 |
| Shares | 1.84M | 63 | 1.71M | −123.8K (−6.7%) |
| Value | $10.5M | $0 | $6.81M | −$3.65M (−34.9%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 19,473 | $78.0K | 0.00% |
| Vivaldi Capital Management, LLC | 24,000 | $60.0K | 0.02% |
| Northern Trust Corp | 10,296 | $41.0K | 0.00% |
| Cambridge Trust Co | 47 | $0 | 0.00% |
| Captrust Financial Advisors | 13 | $0 | 0.00% |
| Creative Planning | 63 | $0 | 0.00% |
Sold out (3)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Millennium Management LLC | 38,040 | $217.0K |
| Harel Insurance Investments & Financial Services Ltd. | 2,958 | $16.0K |
| Advisor Group Holdings, Inc. | 82 | $0 |
Not filed for Q1 2022 yet (1)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Reilly Financial Advisors, LLC | 63 | $0 |